Phase 3 Peripheral Neuropathy Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been confirmed through a tissue test (biopsy) to have Stage III colorectal cancer (cancer of the colon or rectum).
- People who are planned to receive a specific chemotherapy regimen called modified FOLFOX-6.
- People who have no medical reasons preventing them from receiving chemotherapy.
- People aged 18 years or older, of any gender.
- People whose blood test results show healthy enough levels of white blood cells, platelets, and red blood cells (confirm specific numbers with trial site).
- People whose kidneys are working well enough, based on blood and/or urine tests (confirm specific values with trial site).
- People whose liver is working well enough, based on a blood test measuring bilirubin levels (confirm specific values with trial site).
- People who are generally well and able to carry out daily activities, rated 0 or 1 on a standard cancer health scale called the ECOG score (meaning fully active or able to do light activity).
Who may not be able to join:
- People under 18 years of age.
- People who have received certain nerve-damaging chemotherapy drugs (such as oxaliplatin, cisplatin, vincristine, paclitaxel, or docetaxel) within the 6 months before the trial.
- People who already have nerve damage (peripheral neuropathy) caused by another condition, such as diabetes, a brain tumour, or a brain injury.
- People with diabetes or other conditions known to increase the risk of nerve damage, such as an underactive thyroid, autoimmune diseases, or hepatitis C.
- People with a known allergy to oxaliplatin or similar platinum-based chemotherapy drugs.
- People with other inflammatory or physically stressful medical conditions (confirm with trial site).
- People with glaucoma, cataracts, other long-term eye conditions, seizures, diabetes, heart disease, low blood pressure, dizziness, vertigo, Ménière's disease, or other disorders of the brain or nervous system.
- People currently taking multivitamins containing vitamins E, C, or A; tricyclic antidepressants; or certain nerve-related medications such as gabapentin, lamotrigine, carbamazepine, or phenytoin.
- People currently taking the medications amifampridine, bupropion, or donepezil.
- People who have another active cancer that started in a part of the body other than the colon or rectum.
- People who are pregnant or breastfeeding.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 00201111103067
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
variation in 12-item neurotoxicity questionnaire (Ntx-12) total score; variation in pain rating scale score; the percentage of patients with peripheral sensory neuropathy grade ≥ 2
Can't join this trial?
Data last synced from ClinicalTrials.gov: 13 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.